Saturday 17 October 2026
Export ACGN’s income statement to Excel — free account
Aceragen, Inc.
ACGN Healthcare Biotechnology
Aceragen, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $4.9 million. Operating cash flow growth for five consecutive years.
Follow ACGN
Aceragen, Inc. (ACGN) P/E ratio
Aceragen, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (March 2023) to 3.6× (October 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2022 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2022 | 0.0× | — |
| Sep 2022 | 0.0× | — |
| Jun 2019 | 0.0× | — |
| Dec 2018 | 0.0× | — |
| 15 more quarters | Free account |
Against its own ten years
Low 0.0×
High 3.6×
Ten-year median
0.0×
Current reading's percentile
94
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DYAI Dyadic International Inc. compare | n/m |
| NEUP Neuphoria Therapeutics Inc. compare | n/m |
| JSPR Jasper Therapeutics, Inc. compare | n/m |
| TCRX TScan Therapeutics, Inc. compare | n/m |
| ACGN Aceragen, Inc. | n/m |
| ANEB Anebulo Pharmaceuticals, Inc. compare | n/m |
| ATYR aTyr Pharma, Inc. compare | n/m |
| PBM Psyence Biomedical Ltd. compare | 0.2× |
| RADX Radiopharm Theranostics Limited - Sponsored ADR compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)